

Participant	Cohort	Age	Sex	Race	BMI	Days post onset symptoms or days since first vaccine dose		Fraction inspired O <sub>2</sub>	Days since booster	WHO COVID severity scale	COVID Outcome	Co-morbidities
SK-010	Acute COVID-19	36-40	Female	Asian	NA	12	21	NA	5	Recovered	NA	
						24	21					
SK-011	Acute COVID-19	56-60	Female	Caucasian	35.7	6	32	NA	7	Recovered	Type 2 Diabetes, Hypertension, Hyperlipidemia, Obesity	
						13	24					
SK-012	Acute COVID-19	41-45	Male	Caucasian	24.7	8	38	NA	8	Recovered	Asthma, Anxiety, Depression	
						24	38					
SK-013	Acute COVID-19	61-65	Male	NA	NA	6	38	NA	5	Recovered	NA	
						11	28					
SK-014	Acute COVID-19	51-55	Female	Asian	NA	9	21	NA	5	Recovered	NA	
CV-001	mRNA vaccine	36-40	Male	Asian	28.4	0, 7, 14, 21, 28, 35	21	0, 7, 28	NA	NA	NA	
CV-003	mRNA vaccine	31-35	Male	Asian	27.9	0, 10, 20, 28, 35	21	0, 7, 28	NA	NA	Hypothyroidism	
CV-011	mRNA vaccine	36-40	Male	Caucasian	28.6	0, 7, 14, 21, 29, 36	21	0, 7	NA	NA	NA	
CV-012	mRNA vaccine	51-55	Female	Caucasian	28.7	0, 7, 21, 28	21	NA	NA	NA	NA	
CV-022	mRNA vaccine	41-45	Male	Caucasian	22.4	0, 7, 21, 28	21	NA	NA	NA	Facial Cellulitis, GERD	
CV-053	mRNA vaccine	46-50	Female	African-American	NA	0, 7, 21, 28	21	NA	NA	NA	Fibroids, HSV, GERD	
CV-056	mRNA vaccine	51-55	Female	Caucasian	25.4	0, 7, 21, 28	21	NA	NA	NA	NA	
SK-007	HC	36-40	Female	Caucasian	20.4	0	21	NA	NA	NA	NA	
SK-008	HC	36-40	Female	Caucasian	28.6	0	21	NA	NA	NA	NA	

**Supplemental Table 1. Demographic characteristics, clinical features, and outcomes for study participants.**